journal cover

In vivo Prevalence of Alzheimer Biomarkers in Dementia with Lewy Bodies

Dementia and Geriatric Cognitive Disorders

Jul 16, 2019

George P ParaskevasElisabeth N Kapaki

Get paper from

Abstract

Neuropathological studies indicate concomitant Alzheimer's disease (AD) pathology in patients with dementia with Lewy bodies (DLB). To measure cerebrospinal fluid (CSF) levels of β-amyloid peptide with 42 amino acids (Aβ42), total tau protein (τT), and tau phosphorylated at threonine 18...read more

Mentioned in this Paper

Alzheimer's Disease
Biological Markers
Cerebrospinal Fluid
Laboratory
Phosphorylation
Amyloid beta-Peptides
Granulocyte Colony-Stimulating Factor
Lewy Bodies
Tau Proteins
Disease Progression
Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.

Similar Papers Found In These Feeds

Tau Toxicity in the Synapses

Tau toxicity has been implicated in the emergence of synaptic dysfunction in Alzheimer's disease. Here is the latest research on Tau Toxicity in the Synapses.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a chronic neurodegenerative disease. This feed focuses on the underlying role of Tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's.

Tauopathies

Tauopathies are neurodegenerative disorders caused due to misfolding and aggregation of the tau protein in neurofibrillary tangles in the brain. Discover the latest research on tauopathies here.

Tau Aggregation: Genomics

Tau Aggregation is an important characteristic in some neurodegenerative disorders, including Alzheimer’s Disease. Discover the latest research using genomics to understand Tau Aggregation.

Tau Toxicity in the Synapses

Tau toxicity has been implicated in the emergence of synaptic dysfunction in Alzheimer's disease. Here is the latest research on Tau Toxicity in the Synapses.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Alzheimer's Disease: Abeta

Alzheimer's disease (AD) is a chronic neurodegenerative disease associated with accumulation of amyloid plaques, which are comprised of amyloid beta. Here is the latest research in this field.

Lewy Body Disease

Lewy Body Disease, associated with abnormal deposits of proteins like alpha-synuclein in the brain, causes a decline in mental abilities. Here is the latest on this progressive neurological disorder.

© 2019 Meta ULC. All rights reserved

In vivo Prevalence of Alzheimer Biomarkers in Dementia with Lewy Bodies

Dementia and Geriatric Cognitive Disorders

Jul 16, 2019

George P ParaskevasElisabeth N Kapaki

PMID: 31311013

DOI: 10.1159/000500567

Abstract

Neuropathological studies indicate concomitant Alzheimer's disease (AD) pathology in patients with dementia with Lewy bodies (DLB). To measure cerebrospinal fluid (CSF) levels of β-amyloid peptide with 42 amino acids (Aβ42), total tau protein (τT), and tau phosphorylated at threonine 18...read more

Mentioned in this Paper

Alzheimer's Disease
Biological Markers
Cerebrospinal Fluid
Laboratory
Phosphorylation

Similar Papers Found In These Feeds

Related Papers

Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.

Get paper from

/papers/in-vivo-prevalence-of-alzheimer-biomarkers-in/31311013